|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003209,
umls-concept:C0003693,
umls-concept:C0020924,
umls-concept:C0030004,
umls-concept:C0039859,
umls-concept:C0085387,
umls-concept:C0205314,
umls-concept:C0205460,
umls-concept:C0220781,
umls-concept:C0220825,
umls-concept:C0441655,
umls-concept:C0679622,
umls-concept:C1554184,
umls-concept:C1883254
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1994-2-28
|
|
pubmed:abstractText |
A variety of benzylideneoxazoles, -thiazoles, and -imidazoles derived from 2,6-di-tert-butylphenol were prepared and evaluated as dual inhibitors of 5-lipoxygenase and cyclooxygenase in rat basophilic leukemia (RBL-1) cells. The target compounds exhibit varying degrees of selectivity toward the two enzymes. Several compounds are orally active in the rat carageenan footpad edema (CFE) and mycobacterium footpad edema (MFE) antiinflammatory models. Structure-activity relationships are discussed. From this work, (Z)-5-[[3,5-bis(1,1-dimethylethyl)-4- hydroxyphenyl]-methylene]-2-imino-4-thiazolidinone methanesulfonate salt (CI-1004) was identified as a potent dual inhibitor of 5-lipoxygenase (IC50 = 0.77 microM) and cyclooxygenase (IC50 = 0.39 microM), with oral activity (ID40 = 0.6 mg/kg) in the rat MFE model of inflammation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0022-2623
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
21
|
|
pubmed:volume |
37
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
322-8
|
|
pubmed:dateRevised |
2003-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:8295221-Animals,
pubmed-meshheading:8295221-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:8295221-Cyclooxygenase Inhibitors,
pubmed-meshheading:8295221-Imidazoles,
pubmed-meshheading:8295221-Lipoxygenase Inhibitors,
pubmed-meshheading:8295221-Oxazoles,
pubmed-meshheading:8295221-Rats,
pubmed-meshheading:8295221-Structure-Activity Relationship,
pubmed-meshheading:8295221-Thiazoles,
pubmed-meshheading:8295221-Tumor Cells, Cultured
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethylethyl)- 4-hydroxyphenyl]methylene]oxazoles, -thiazoles, and -imidazoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity.
|
|
pubmed:affiliation |
Department of Chemistry, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan 48105.
|
|
pubmed:publicationType |
Journal Article
|
